Latest · Week of 9 November 2026
This Week in Research: Tirzepatide, BPC-157, MOTS-c and Thymosin Alpha-1
Nine new papers on compounds we carry crossed our desk this week, and the most useful ones are the least flashy. Three on tirzepatide ask what happens after the headline result: what it does to the gut's bacteria, what happens to body weight when people stop, and a hospital case that raises a new safety question. There is a BPC-157 review on the liver, a large ICU cohort on thymosin alpha-1, an athlete study on MOTS-c, and two reviews that put retatrutide, tesamorelin and copper peptides in context. What follows is our read of what each one examined and how far it goes.
Read all 9 papers
